s47445
Small moleculeexperimental
Tulrampator is a positive allosteric modulator (PAM) of the AMPA receptor (AMPAR), an ionotropic glutamate receptor, which is under development by RespireRx Pharmaceuticals and Servier for the treatment of major depressive disorder, Alzheimer's disease, dementia, and mild cognitive impairment. Tulrampator was in phase II clinical trial for depression, but failed to show superiority over placebo. There are also phase II clinical trials for Alzheimer's disease and phase I trials for dementia and mild cognitive impairment. — Wikipedia
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2015 (NCT02626572)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Glutamate receptor AMPA 1/2ACTIVATOR
Glutamate receptor AMPA 1/2 activator
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02805439 | Phase 2 | Mar 1, 2016 | ADIR Association, Servier |
| NCT02626572 | Phase 2 | Feb 1, 2015 | Servier |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Servier | For profit | 2 | 2 | 1 | 2015 |
| ADIR Association | Academic/Hospital | 1 | 0 | 1 | 2016 |
2 organizations
Page 1 / 1